SCHEMBL25993223

SCHEMBL25993223

C=CCCC(C(=O)NC)N1Cc2cc(C)ccc2C1=C

nearest known ligand 0.35

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 4/20 0.33
▸ GAA P10253 1/20 0.32
▸ POLB P06746 2/20 0.31
▸ NAMPT P43490 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ METAP1 P53582 1/20 0.31
▸ SLC6A2 P23975 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ SDCBP O00560 2/20 0.30
▸ SDC2 P34741 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25993259 0.91 THRB (0.33) THRBGAAPOLBNAMPTLMNA
SCHEMBL26020707 0.89 THRB (0.43) THRBGAAPOLBLMNASDCBP
SCHEMBL20936104 0.88 — —
SCHEMBL25986037 0.87 THRB (0.33) THRBGAAPOLBLMNASDCBP
SCHEMBL26017679 0.85 THRB (0.41) THRBGAAPOLBNAMPTLMNA
SCHEMBL25993979 0.83 PRMT5 (0.33) POLBNAMPTSDCBPSDC2
SCHEMBL25982147 0.82 PRMT5 (0.34) NAMPT
SCHEMBL24790325 0.82 DRD2 (0.39) —
SCHEMBL25993269 0.80 METAP1 (0.31) METAP1
SCHEMBL25993234 0.79 THRB (0.44) THRBGAAPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4076650-B1 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2024-02-28 — — EP disclosed
EP-4306111-A2 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-01-17 — — EP disclosed
EP-3820573-B1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2023-08-09 — — EP disclosed
Send feedback